GlassScriptPhysician profile
Andrew J Scheman
NPI 1881674828
$6,367.70
in general payments reported to CMS, 2019-2025
27 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $412 · 2021: $906 · 2022: $932 · 2023: $974 · 2024: $1,117 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,050.40 |
| Education | $196.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,317.57 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $846.01 | 2019-2025 | |
| Leo Pharma INC. | $613.54 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $586.36 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $488.87 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $455.68 | 2019-2025 | Aklief, Dysport, Nemluvio |
| Lilly USA, LLC | $354.17 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $277.94 | 2019-2022 | |
| Janssen Biotech, INC. | $220.44 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $170.54 | 2022-2025 | Opzelura |
| Pfizer INC. | $156.48 | 2019-2025 | |
| Biofrontera INC. | $145.25 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $132.17 | 2019-2021 | |
| Almirall LLC | $90.18 | 2019-2021 | |
| Dermira, INC. | $89.42 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $64.21 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $60.48 | 2023-2024 | Sotyktu |
| Amgen INC. | $59.60 | 2023-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.24 | 2023-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $42.68 | 2021 | |
| Genentech USA, INC. | $29.89 | 2023 | Xolair |
| Allergan, INC. | $22.19 | 2022 | |
| Encore Dermatology INC. | $21.02 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.63 | 2024 | Ycanth |
| Celgene Corporation | $19.10 | 2019 | |
| Botanix Sb INC | $19.04 | 2025 | Sofdra |
| Glenmark Therapeutics INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Scheman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.